BAKER BROS. ADVISORS LP Q1 2018 Filing
Filed May 15, 2018
Portfolio Value
$11.8B
Holdings
114
Report Date
Q1 2018
Filing Type
13F-HR
All Holdings (114 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | SELBUSDSelecta Biosciences, Inc. | 93,750 | $955.0M | 8.09% | |
| 102 | —Ra Pharmaceuticals, Inc. | 177,952 | $945.0M | 8.01% | |
| 103 | I9DNArbutus Biopharma Corporation | 180,582 | $903.0M | 7.65% | |
| 104 | —Ritter Pharmaceuticals, Inc. | 279,999 | $762.0M | 6.46% | |
| 105 | —Proteon Therapeutics, Inc. | 298,591 | $746.0M | 6.32% | |
| 106 | —Affimed N.V. | 400,000 | $740.0M | 6.27% | |
| 107 | —T2 Biosystems, Inc. | 100,000 | $649.0M | 5.50% | |
| 108 | —Akari Therapeutics, Plc | 339,833 | $618.0M | 5.24% | |
| 109 | —Molecular Templates, Inc. | 72,412 | $579.0M | 4.91% | |
| 110 | FLGTFulgent Genetics, Inc. | 125,000 | $500.0M | 4.24% | |
| 111 | —Immune Design Corp. | 148,937 | $491.0M | 4.16% | |
| 112 | —BioDelivery Sciences International, Inc. | 210,021 | $473.0M | 4.01% | |
| 113 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $77.0M | 0.65% | |
| 114 | —BioTime, Inc. | 20,084 | $2.0M | 0.02% |
PreviousPage 2 of 2